Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Tevogen Bio Holdings Inc (TVGNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: TVGNW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -70% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.67 | 52 Weeks Range 0.01 - 0.15 | Updated Date 06/12/2025 |
52 Weeks Range 0.01 - 0.15 | Updated Date 06/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -578.29% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 20805703 |
Shares Outstanding - | Shares Floating 20805703 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Tevogen Bio Holdings Inc
Company Overview
History and Background
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for viral infections and cancers. Founded relatively recently, it's focused on T-cell directed immunotherapy.
Core Business Areas
- Immunotherapy Development: Development of allogeneic T-cell immunotherapies for treatment of viral infections and cancers. Includes research, preclinical and clinical trials, and manufacturing.
Leadership and Structure
The company is led by a management team with expertise in biotechnology and clinical development. Detailed organizational structure is not publicly available in depth.
Top Products and Market Share
Key Offerings
- Tevogen Bio Holdings Inc's Lead Product: Tevogen Bio Holdings Inc's lead product is for the treatment of cancers caused by viral infections. Market share data is not currently available. Competitors include companies developing similar T-cell therapies.
Market Dynamics
Industry Overview
The immunotherapy market is rapidly growing, driven by advances in T-cell therapies and the increasing prevalence of cancer and viral infections.
Positioning
Tevogen Bio Holdings Inc aims to establish a strong position in the immunotherapy market by developing novel and effective allogeneic T-cell therapies. Competitive advantages are still nascent given clinical trial stage.
Total Addressable Market (TAM)
The TAM for immunotherapy is estimated to be in the tens of billions of dollars globally. Tevogen Bio Holdings Inc is positioned to capture a portion of this market if its therapies are successful.
Upturn SWOT Analysis
Strengths
- Novel Immunotherapy Platform
- Experienced Management Team
- Potential for High Growth
- Focus on Unmet Medical Needs
Weaknesses
- Limited Financial Resources
- Early-Stage Clinical Development
- Reliance on Clinical Trial Success
- Limited Public Information
Opportunities
- Partnerships with Larger Pharmaceutical Companies
- Expansion into New Therapeutic Areas
- Accelerated Regulatory Approvals
- Increasing Demand for Immunotherapies
Threats
- Competition from Established Pharmaceutical Companies
- Clinical Trial Failures
- Regulatory Hurdles
- Economic Downturn
Competitors and Market Share
Key Competitors
- GILD
- BMY
- MRTX
- NKGN
Competitive Landscape
Tevogen Bio Holdings Inc faces significant competition from established pharmaceutical companies with greater resources and established market presence. It will be difficult for the company to take significant market share.
Growth Trajectory and Initiatives
Historical Growth: Not applicable due to limited history.
Future Projections: Future growth depends on successful clinical trials and regulatory approvals. Analyst estimates are not widely available.
Recent Initiatives: Focus on advancing lead product through clinical trials and securing funding.
Summary
Tevogen Bio Holdings Inc is an early-stage biotechnology company with a focus on immunotherapy. It is positioned in a rapidly growing market but faces significant competition and risks associated with clinical development. Success hinges on positive clinical trial results and securing adequate funding. The company needs to build a strong intellectual property position and develop strategic partnerships to thrive.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Market research reports
- Analyst reports (limited)
Disclaimers:
This analysis is based on publicly available information and does not constitute financial advice. The information is subject to change without notice. Investing in early-stage biotechnology companies involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tevogen Bio Holdings Inc
Exchange NASDAQ | Headquaters Warren, NJ, United States | ||
IPO Launch date 2022-01-03 | Co-Founder, CEO & Chairperson Dr. Ryan H. Saadi M.D., M.P.H, M.P.H. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 18 | Website https://tevogen.com |
Full time employees 18 | Website https://tevogen.com | ||
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients. It is also developing TVGN 920 for treating cervical cancer; TVGN 960 for treating oropharyngeal cancer; TVGN 601 for treating MS; and TVGN 930 for treating EBV-associated lymphomas. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.